Review article · 2014 · Open access

Aripiprazole versus other atypical antipsychotics for schizophrenia

Priya Khanna, Tao Suo, Katja Komossa, Huaixing Ma, Christine Rummel‐Kluge, Hany George G El-Sayeh, Stefan Leucht, Jun Xia

Cochrane Database of Systematic Reviews, 2016(10), CD006569 · Published 2 January 2014 · DOI 10.1002/14651858.cd006569.pub5

Open full textView at the publisherCite this paper

In brief

“Aripiprazole versus other atypical antipsychotics for schizophrenia” is a 2014 review article by Priya Khanna and 7 co-authors, published in Cochrane Database of Systematic Reviews. OpenAlex counts 165 citations as of 20 November 2026, which puts it in the top 5% of works published in 2014 by citations. It is open access: the full text is free to read at Europe PMC (PubMed Central).

Citations
165
Most cited in
2017 (16)
Field-weighted impact
2.23
References
222
Authors
8

Abstract

BACKGROUND: In most western industrialised countries, second generation (atypical) antipsychotics are recommended as first-line drug treatments for people with schizophrenia. In this review, we specifically examine how the efficacy and tolerability of one such agent - aripiprazole - differs from that of other comparable second generation antipsychotics. OBJECTIVES: To review the effects of aripiprazole compared with other atypical antipsychotics for people with schizophrenia and schizophrenia-like psychoses. SEARCH METHODS: We searched the Cochrane Schizophrenia Group Trials Register (November 2012), inspected references of all identified studies for further trials and contacted relevant pharmaceutical companies, drug approval agencies and authors of trials for additional information. SELECTION CRITERIA: We included all randomised clinical trials (RCTs) comparing aripiprazole (oral) with oral and parenteral forms of amisulpride, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone or zotepine for people with schizophrenia or schizophrenia-like psychoses. DATA COLLECTION AND ANALYSIS: We extracted data independently. For dichotomous data we calculated risk ratios (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis based on a random-effects model. Where possible, we calculated illustrative comparative risks for primary outcomes. For continuous data, we calculated mean differences (MD), again based on a random-effects model. We assessed risk of bias for each included study and used GRADE approach to rate quality of evidence. MAIN RESULTS: We now have included 174 trials involving 17,244 participants. Aripiprazole was compared with clozapine, quetiapine, risperidone, ziprasidone and olanzapine. The overall number of participants leaving studies early was 30% to 40%, limiting validity (no differences between groups).When compared with clozapine, there were no significant differences for global state (no clinically significant response, n = 2132, 29 RCTs, low quality evidence); mental state (BPRS, n = 426, 5 RCTs, very low quality evidence); or leaving the study early for any reason (n = 240, 3 RCTs, very low quality evidence). Quality of life score using the WHO-QOL-100 scale demonstrated significant difference, favouring aripiprazole (n = 132, 2 RCTs, RR 2.59 CI 1.43 to 3.74, very low quality evidence). General extrapyramidal symptoms (EPS) were no different between groups (n = 520, 8 RCTs,very low quality evidence). No study reported general functioning or service use.When compared with quetiapine, there were no significant differences for global state (n = 991, 12 RCTs, low quality evidence); mental state (PANSS positive symptoms, n = 583, 7 RCTs, very low quality evidence); leaving the study early for any reason (n = 168, 2 RCTs, very low quality evidence), or general EPS symptoms (n = 348, 4 RCTs, very low quality evidence). Results were significantly in favour…

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Khanna, P., Suo, T., Komossa, K., Ma, H., Rummel‐Kluge, C., El-Sayeh, H. G. G., Leucht, S., & Xia, J. (2014). Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews, 2016(10), CD006569. https://doi.org/10.1002/14651858.cd006569.pub5

MLA 9

Khanna, Priya, et al. “Aripiprazole versus other atypical antipsychotics for schizophrenia.” Cochrane Database of Systematic Reviews, vol. 2016, no. 10, 2014, p. CD006569. https://doi.org/10.1002/14651858.cd006569.pub5.

Chicago

Khanna, Priya, Tao Suo, Katja Komossa, Huaixing Ma, Christine Rummel‐Kluge, Hany George G El-Sayeh, Stefan Leucht, and Jun Xia. 2014. “Aripiprazole versus other atypical antipsychotics for schizophrenia.” Cochrane Database of Systematic Reviews 2016 (10): CD006569. https://doi.org/10.1002/14651858.cd006569.pub5.

Harvard

Khanna, P. et al. (2014) ‘Aripiprazole versus other atypical antipsychotics for schizophrenia’, Cochrane Database of Systematic Reviews, 2016(10), p. CD006569. doi:10.1002/14651858.cd006569.pub5.

IEEE

P. Khanna et al., “Aripiprazole versus other atypical antipsychotics for schizophrenia,” Cochrane Database of Systematic Reviews, vol. 2016, no. 10, p. CD006569, 2014, doi: 10.1002/14651858.cd006569.pub5.

BibTeX

@article{khanna2014aripiprazole,
  title     = {{Aripiprazole versus other atypical antipsychotics for schizophrenia}},
  author    = {Khanna, Priya and Suo, Tao and Komossa, Katja and Ma, Huaixing and Rummel‐Kluge, Christine and El-Sayeh, Hany George G and Leucht, Stefan and Xia, Jun},
  journal   = {Cochrane Database of Systematic Reviews},
  year      = {2014},
  volume    = {2016},
  number    = {10},
  pages     = {CD006569},
  doi       = {10.1002/14651858.cd006569.pub5},
  url       = {https://doi.org/10.1002/14651858.cd006569.pub5}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
20171616
201888
20191313
202055
20211010
202255
202377
202444
202599
202633

Its field-weighted citation impact is 2.23: it has been cited 2.23 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment

  • aripiprazole
  • atypical antipsychotics
  • schizophrenia
  • schizophrenia-like psychoses
  • clozapine
  • quetiapine
  • risperidone
  • olanzapine

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Khanna, P., Suo, T., Komossa, K., Ma, H., Rummel‐Kluge, C., El-Sayeh, H. G. G., Leucht, S., & Xia, J. (2014). Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews, 2016(10), CD006569. https://doi.org/10.1002/14651858.cd006569.pub5

How many times has this paper been cited?

165 times, according to OpenAlex on 20 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Europe PMC (PubMed Central): sign in and open the full text from this page.

Who wrote this paper?

Priya Khanna, Tao Suo, Katja Komossa, Huaixing Ma, Christine Rummel‐Kluge, Hany George G El-Sayeh, Stefan Leucht, Jun Xia.

What is the DOI of this paper?

10.1002/14651858.cd006569.pub5, permanently at https://doi.org/10.1002/14651858.cd006569.pub5. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 20 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.